vs
ANI PHARMACEUTICALS INC（ANIP）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Ecovyst Inc.的1.2倍（$247.1M vs $199.4M），Ecovyst Inc.同比增速更快（34.0% vs 29.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $22.9M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 18.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
ANIP vs ECVT — 直观对比
营收规模更大
ANIP
是对方的1.2倍
$199.4M
营收增速更快
ECVT
高出4.3%
29.6%
自由现金流更多
ANIP
多$6.2M
$22.9M
两年增速更快
ANIP
近两年复合增速
18.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $199.4M |
| 净利润 | $27.5M | — |
| 毛利率 | — | 23.4% |
| 营业利润率 | 14.1% | 10.9% |
| 净利率 | 11.1% | — |
| 营收同比 | 29.6% | 34.0% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPECVT
| Q4 25 | $247.1M | $199.4M | ||
| Q3 25 | $227.8M | $204.9M | ||
| Q2 25 | $211.4M | $176.1M | ||
| Q1 25 | $197.1M | $143.1M | ||
| Q4 24 | $190.6M | $148.9M | ||
| Q3 24 | $148.3M | $153.9M | ||
| Q2 24 | $138.0M | $154.0M | ||
| Q1 24 | $137.4M | $141.6M |
净利润ANIPECVT
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-79.3M | ||
| Q2 25 | $8.5M | $6.0M | ||
| Q1 25 | $15.7M | $-3.6M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $14.3M | ||
| Q2 24 | $-2.3M | $8.3M | ||
| Q1 24 | $18.2M | $1.2M |
毛利率ANIPECVT
| Q4 25 | — | 23.4% | ||
| Q3 25 | — | 25.4% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 29.3% | ||
| Q2 24 | — | 27.3% | ||
| Q1 24 | — | 23.5% |
营业利润率ANIPECVT
| Q4 25 | 14.1% | 10.9% | ||
| Q3 25 | 15.9% | 13.8% | ||
| Q2 25 | 6.6% | 9.0% | ||
| Q1 25 | 13.3% | -0.7% | ||
| Q4 24 | -2.3% | 15.1% | ||
| Q3 24 | -13.8% | 17.9% | ||
| Q2 24 | 3.7% | 14.1% | ||
| Q1 24 | 14.8% | 9.5% |
净利率ANIPECVT
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -38.7% | ||
| Q2 25 | 4.0% | 3.4% | ||
| Q1 25 | 8.0% | -2.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 9.3% | ||
| Q2 24 | -1.7% | 5.4% | ||
| Q1 24 | 13.2% | 0.9% |
每股收益（稀释后）ANIPECVT
| Q4 25 | $1.14 | $0.06 | ||
| Q3 25 | $1.13 | $-0.69 | ||
| Q2 25 | $0.36 | $0.05 | ||
| Q1 25 | $0.69 | $-0.03 | ||
| Q4 24 | $-0.45 | $-0.26 | ||
| Q3 24 | $-1.27 | $0.12 | ||
| Q2 24 | $-0.14 | $0.07 | ||
| Q1 24 | $0.82 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $197.2M |
| 总债务越低越好 | — | $392.6M |
| 股东权益账面价值 | $540.7M | $603.4M |
| 总资产 | $1.4B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资ANIPECVT
| Q4 25 | $285.6M | $197.2M | ||
| Q3 25 | $262.6M | $82.0M | ||
| Q2 25 | $217.8M | $69.6M | ||
| Q1 25 | $149.8M | $127.5M | ||
| Q4 24 | $144.9M | $131.4M | ||
| Q3 24 | $145.0M | $123.5M | ||
| Q2 24 | $240.1M | $83.3M | ||
| Q1 24 | $228.6M | $103.1M |
总债务ANIPECVT
| Q4 25 | — | $392.6M | ||
| Q3 25 | — | $854.8M | ||
| Q2 25 | — | $856.6M | ||
| Q1 25 | — | $859.0M | ||
| Q4 24 | — | $860.8M | ||
| Q3 24 | — | $862.7M | ||
| Q2 24 | — | $862.4M | ||
| Q1 24 | — | $866.2M |
股东权益ANIPECVT
| Q4 25 | $540.7M | $603.4M | ||
| Q3 25 | $505.8M | $607.9M | ||
| Q2 25 | $436.8M | $692.4M | ||
| Q1 25 | $418.6M | $698.7M | ||
| Q4 24 | $403.7M | $700.5M | ||
| Q3 24 | $405.9M | $729.4M | ||
| Q2 24 | $455.8M | $717.3M | ||
| Q1 24 | $452.0M | $711.4M |
总资产ANIPECVT
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $920.8M | $1.8B | ||
| Q1 24 | $914.5M | $1.8B |
负债/权益比ANIPECVT
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $41.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $22.9M |
| 自由现金流率自由现金流/营收 | 11.8% | 11.5% |
| 资本支出强度资本支出/营收 | 0.5% | 9.4% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | $69.9M |
8季度趋势，按日历期对齐
经营现金流ANIPECVT
| Q4 25 | $30.4M | $41.8M | ||
| Q3 25 | $44.1M | $55.3M | ||
| Q2 25 | $75.8M | $33.0M | ||
| Q1 25 | $35.0M | $10.3M | ||
| Q4 24 | $15.9M | $43.5M | ||
| Q3 24 | $12.5M | $59.9M | ||
| Q2 24 | $17.4M | $10.0M | ||
| Q1 24 | $18.3M | $36.5M |
自由现金流ANIPECVT
| Q4 25 | $29.1M | $22.9M | ||
| Q3 25 | $38.0M | $53.2M | ||
| Q2 25 | $71.8M | $7.8M | ||
| Q1 25 | $32.5M | $-14.0M | ||
| Q4 24 | $13.5M | $30.9M | ||
| Q3 24 | $7.7M | $53.6M | ||
| Q2 24 | $13.0M | $-9.3M | ||
| Q1 24 | $13.7M | $19.1M |
自由现金流率ANIPECVT
| Q4 25 | 11.8% | 11.5% | ||
| Q3 25 | 16.7% | 26.0% | ||
| Q2 25 | 34.0% | 4.4% | ||
| Q1 25 | 16.5% | -9.8% | ||
| Q4 24 | 7.1% | 20.7% | ||
| Q3 24 | 5.2% | 34.9% | ||
| Q2 24 | 9.4% | -6.1% | ||
| Q1 24 | 10.0% | 13.5% |
资本支出强度ANIPECVT
| Q4 25 | 0.5% | 9.4% | ||
| Q3 25 | 2.7% | 1.0% | ||
| Q2 25 | 1.9% | 14.4% | ||
| Q1 25 | 1.3% | 16.9% | ||
| Q4 24 | 1.3% | 8.5% | ||
| Q3 24 | 3.2% | 4.1% | ||
| Q2 24 | 3.2% | 12.5% | ||
| Q1 24 | 3.3% | 12.3% |
现金转化率ANIPECVT
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 5.52× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.21× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | 1.00× | 29.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
